Jim Simons Corvus Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

$63.4 Billion
Q4 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 390,688 shares of CRVS stock, worth $1.91 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

390,688

Previous 386,588 1.06%

Holding current value

$1.91 Million

Previous $2.04 Million 0.49%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$4.55 - $9.56 $18,655 - $39,196	4,100 Added 1.06%	390,688 $2.03 Million
Q3 2024 Nov 13, 2024	SELL	$1.78 - $5.92 $315,672 - $1.05 Million	-177,344 Reduced 31.45%	386,588 $2.04 Million
Q2 2024 Aug 09, 2024	SELL	$1.36 - $2.29 $99,416 - $167,399	-73,100 Reduced 11.48%	563,932 $1.03 Million
Q1 2024 May 13, 2024	BUY	$1.76 - $2.41 $87,296 - $119,536	49,600 Added 8.44%	637,032 $1.13 Million
Q4 2023 Feb 13, 2024	BUY	$1.08 - $1.92 $178,944 - $318,122	165,689 Added 39.29%	587,432 $1.03 Million
Q3 2023 Nov 14, 2023	SELL	$1.41 - $2.97 $95,781 - $201,752	-67,930 Reduced 13.87%	421,743 $616,000
Q2 2023 Aug 11, 2023	SELL	$1.0 - $3.86 $16,359 - $63,145	-16,359 Reduced 3.23%	489,673 $1.12 Million
Q1 2023 May 12, 2023	SELL	$0.65 - $0.92 $92,690 - $131,192	-142,600 Reduced 21.98%	506,032 $460,000
Q4 2022 Feb 13, 2023	SELL	$0.74 - $1.04 $241,896 - $339,962	-326,887 Reduced 33.51%	648,632 $551,000
Q3 2022 Nov 14, 2022	BUY	$0.71 - $1.17 $8,936 - $14,726	12,587 Added 1.31%	975,519 $798,000
Q2 2022 Aug 12, 2022	BUY	$0.87 - $2.03 $53,766 - $125,453	61,800 Added 6.86%	962,932 $953,000
Q1 2022 May 13, 2022	SELL	$1.46 - $2.48 $208,196 - $353,648	-142,600 Reduced 13.66%	901,132 $1.48 Million
Q4 2021 Feb 11, 2022	BUY	$2.34 - $5.31 $1 Million - $2.28 Million	429,362 Added 69.89%	1,043,732 $2.52 Million
Q3 2021 Nov 12, 2021	SELL	$1.89 - $8.53 $82,593 - $372,761	-43,700 Reduced 6.64%	614,370 $2.97 Million
Q2 2021 Aug 13, 2021	SELL	$2.46 - $3.14 $13,284 - $16,956	-5,400 Reduced 0.81%	658,070 $1.76 Million
Q1 2021 May 13, 2021	SELL	$2.86 - $4.77 $382,096 - $637,272	-133,600 Reduced 16.76%	663,470 $2.04 Million
Q4 2020 Feb 10, 2021	SELL	$3.56 - $4.86 $277,430 - $378,739	-77,930 Reduced 8.91%	797,070 $2.84 Million
Q3 2020 Nov 13, 2020	SELL	$2.6 - $5.37 $407,940 - $842,553	-156,900 Reduced 15.2%	875,000 $3.51 Million
Q2 2020 Aug 13, 2020	BUY	$2.01 - $4.05 $203,411 - $409,860	101,200 Added 10.87%	1,031,900 $2.81 Million
Q1 2020 May 14, 2020	BUY	$1.74 - $5.98 $42,630 - $146,510	24,500 Added 2.7%	930,700 $1.96 Million
Q4 2019 Feb 13, 2020	BUY	$2.56 - $5.44 $139,320 - $296,055	54,422 Added 6.39%	906,200 $4.93 Million
Q3 2019 Nov 13, 2019	BUY	$3.01 - $6.5 $56,226 - $121,420	18,680 Added 2.24%	851,778 $2.56 Million
Q2 2019 Aug 12, 2019	BUY	$3.3 - $4.58 $169,613 - $235,402	51,398 Added 6.58%	833,098 $3.12 Million
Q1 2019 May 14, 2019	BUY	$3.75 - $4.97 $447,750 - $593,418	119,400 Added 18.03%	781,700 $3.14 Million
Q4 2018 Feb 13, 2019	BUY	$3.29 - $8.94 $2.18 Million - $5.92 Million	662,300 New	662,300 $2.43 Million

Others Institutions Holding CRVS

# of Institutions

Shares Held

39.9M

Call Options Held

1.95M

Put Options Held

462K

View Full List

About Corvus Pharmaceuticals, Inc.

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $227M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

More about CRVS

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account